Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report
Slowly developing immune-mediated diabetes, often called latent autoimmune diabetes in adults, is characterized by the presence of autoantibodies (ATs) to glutamic acid decarboxylase (GADA), the patient's age at the onset over 35 years, and the absence of the need for insulin therapy for 6-12 m...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4da7d16d4cf9412a95303ac183b7e4ae |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4da7d16d4cf9412a95303ac183b7e4ae |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4da7d16d4cf9412a95303ac183b7e4ae2021-11-14T09:00:23ZSlowly evolving, immune-mediated diabetes in 14-year-old patient: a case report2072-03512072-037810.14341/DM12397https://doaj.org/article/4da7d16d4cf9412a95303ac183b7e4ae2021-02-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12397https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Slowly developing immune-mediated diabetes, often called latent autoimmune diabetes in adults, is characterized by the presence of autoantibodies (ATs) to glutamic acid decarboxylase (GADA), the patient's age at the onset over 35 years, and the absence of the need for insulin therapy for 6-12 months to 6 years from the moment of diagnosis, according to the WHO classification of 2019, refers to hybrid forms of diabetes mellitus (DM). In this article, we present a case history of slowly developing immune-mediated diabetes in a 14-year-old boy who was transferred from metformin monotherapy and a diet with restriction of digestible carbohydrates to the intensified insulin therapy only 4 years after the onset of diabetes mellitus with a glycated hemoglobin (HbA1c) level of less than 6.5% throughout the disease. As a result of the studies, the patient was found to have a homozygous genotype highly predisposing to the development of Type 1 Diabetes Mellitus (T1DM), as well as increased levels of ATs to GADA and tyrosine phosphatase (IA-2A). The initially preserved level of basal C-peptide and the clinical course of the disease in this patient do not allow us to classify this case as a classic variant of the course of Type 1 Diabetes Mellitus.M. R. RagimovD. D. OmelchukL. I. IbragimovaO. S. DerevyankoT. V. NikonovaEndocrinology Research Centrearticleslowly evolvingimmune-mediated diabeteslong-standing autoimmunityresidual insulin secretionNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 24, Iss 1, Pp 70-73 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
slowly evolving immune-mediated diabetes long-standing autoimmunity residual insulin secretion Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
slowly evolving immune-mediated diabetes long-standing autoimmunity residual insulin secretion Nutritional diseases. Deficiency diseases RC620-627 M. R. Ragimov D. D. Omelchuk L. I. Ibragimova O. S. Derevyanko T. V. Nikonova Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| description |
Slowly developing immune-mediated diabetes, often called latent autoimmune diabetes in adults, is characterized by the presence of autoantibodies (ATs) to glutamic acid decarboxylase (GADA), the patient's age at the onset over 35 years, and the absence of the need for insulin therapy for 6-12 months to 6 years from the moment of diagnosis, according to the WHO classification of 2019, refers to hybrid forms of diabetes mellitus (DM). In this article, we present a case history of slowly developing immune-mediated diabetes in a 14-year-old boy who was transferred from metformin monotherapy and a diet with restriction of digestible carbohydrates to the intensified insulin therapy only 4 years after the onset of diabetes mellitus with a glycated hemoglobin (HbA1c) level of less than 6.5% throughout the disease. As a result of the studies, the patient was found to have a homozygous genotype highly predisposing to the development of Type 1 Diabetes Mellitus (T1DM), as well as increased levels of ATs to GADA and tyrosine phosphatase (IA-2A). The initially preserved level of basal C-peptide and the clinical course of the disease in this patient do not allow us to classify this case as a classic variant of the course of Type 1 Diabetes Mellitus. |
| format |
article |
| author |
M. R. Ragimov D. D. Omelchuk L. I. Ibragimova O. S. Derevyanko T. V. Nikonova |
| author_facet |
M. R. Ragimov D. D. Omelchuk L. I. Ibragimova O. S. Derevyanko T. V. Nikonova |
| author_sort |
M. R. Ragimov |
| title |
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| title_short |
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| title_full |
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| title_fullStr |
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| title_full_unstemmed |
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| title_sort |
slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report |
| publisher |
Endocrinology Research Centre |
| publishDate |
2021 |
| url |
https://doaj.org/article/4da7d16d4cf9412a95303ac183b7e4ae |
| work_keys_str_mv |
AT mrragimov slowlyevolvingimmunemediateddiabetesin14yearoldpatientacasereport AT ddomelchuk slowlyevolvingimmunemediateddiabetesin14yearoldpatientacasereport AT liibragimova slowlyevolvingimmunemediateddiabetesin14yearoldpatientacasereport AT osderevyanko slowlyevolvingimmunemediateddiabetesin14yearoldpatientacasereport AT tvnikonova slowlyevolvingimmunemediateddiabetesin14yearoldpatientacasereport |
| _version_ |
1718429462518824960 |